

Competitor Fact Sheet: Cerament®



For Biocomposites' employees and authorized distributors internal use only.



Feature	STIMULAN®	Cerament® Bonesupport® AB
Composition	Powder: 100% Pharmaceutical-grade CaSO_4 Mixing solution: Sterile water	Powder: 60% CaSO_4 , 40% Hydroxyapatite (HA) Mixing solution: Liquid containing iohexol ⁵
Cleared for infected sites	Yes ¹	No - contraindicated ⁴
Available sizes	Rapid Cure: 3cc, 5cc, 10cc, 20cc Kit: 5cc, 10cc	5cc, 10cc, 18cc
Setting options and times	Rapid Cure: 4 minutes Kit (Standard set): 8 minutes	Standard set: 15 minutes ⁶
Formats	3 bead sizes, 2 bullet sizes, paste, injectable	Injectable, moldable ^{4, 5}
Bead and bullet sizes	3.0mm, 4.8mm, 6.0mm beads 7.0mm, 9.0mm bullets	Not available
Bead or bullet mat included	<ul style="list-style-type: none"> Universal bead mats are included in 5cc, 10cc and 20cc boxes A combination bead and bullet mat is included in the 3cc box A bullet mat and introducer system is available for order 	Not available
Impurities	No impurities ²	Unknown
Claimed absorption rate	4-8 weeks ¹	6-12 months ⁵
Fully absorbs	Yes ¹	No ²

Feature	STIMULAN®	Cerament® Bonesupport® AB
pH	Physiologic ²	Slightly acidic ²
Hydrophilic or Hydrophobic	Hydrophilic ²	Hydrophilic ²
Compressive strength	Wet: 21 MPa Dry: 14.96 MPa ²	Wet: 5-8 MPa Dry: 40-60 MPa ⁷
Third body damage	No third body damage to articulating surfaces ²	May cause third body damage ²
Peer-reviewed evidence	382 ²	150 ⁸
Key selling points and weaknesses	(+) Cleared for use in infected sites ¹ (+) Only STIMULAN undergoes a proprietary DRy26® recrystallization method which consists of 26 steps over 6 weeks and results in its consistent and reliable performance ³ (+) 100% Pharmaceutical-grade CaSO ₄ (+) Contains no HA or insoluble impurities ² (+) Absorbs at an optimal rate and leaves no nidus for infection ² (+) No third body damage and no precaution against use in articulating surfaces ^{1,2} (+) Fast and standard set options available (+) Bead and bullet formats available (+) Comprehensive support network for our customers and hospitals (+) 50,000 cases per year ²	(+) Radiopaque during injection ⁵ (+) Drillable ⁵ (-) Contraindicated for infected sites ^{4,7} (-) Contraindicated for patients with a history of serious reaction to iodine based radio contrast agents (iohexol component) ^{4,7} (-) Contains HA, which has a slow and incomplete absorption rate ² (-) HA can cause a long-term nidus for infection ² (-) Precaution to avoid intra-articular use ⁴ (-) May cause third body damage ² (-) No fast setting option available ⁶ * (+) = competitor selling points (-) = competitor weaknesses

References:

1. Biocomposites Ltd, STIMULAN Instructions for Use.
2. Biocomposites, Data on file.
3. Cooper, J.J., Method of producing surgical grade calcium sulphate; Patent. 1999.
4. BONESUPPORT® AB Instructions for use CERAMENT™ Bone Void Filler – A 0210. Document No. IFU 0007-08 en 2014-06.
5. BONESUPPORT® AB CERAMENT™ Bone Void Filler Brochure. PR 0346-03 en US.
6. BONESUPPORT® AB CERAMENT™ Bone Void Filler Mixing Guide. PR 0647-01 en EU/US.
7. BONESUPPORT® AB CERAMENT™ Bone Void Filler Product Fact Sheet. PR 0649-01 en EU/US.
8. BONESUPPORT® AB Website: <https://www.bonesupport.com/en-eu/>

For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time. This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2020, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorized copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP I204599 B1, US 6780391, EP 2594231 B1, US 88883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1, US I0390954
 Patents pending: GB1502655.2, US I5/040075, CN 201610089710.5, GB1704688.9, EP I8275044.8, US I5/933936, CN I08619579A